Ifosfamide in non-small cell lung cancer

C. Boni, F. Zanelli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20-25%. These results are improved when it is used in combination with cisplatin and mitomycin C. Moreover, in recent years, several new drugs like gemcitabine, taxanes and vinorelbine have been identified, and combinations of two or three drugs have been tested in patients with advanced NSCLC. This paper reviews the main studies recently conducted for the treatment of NSCLC, considering the results obtained by ifosfamide alone and in combination. Three-drug regimens including first-generation cytostatic agents achieve a response rate of about 40% and median survival of 10 months. In combinations with new drugs, ifosfamide shows an improvement in response rate (50%) with a median survival of more than 1 year. Open questions in the treatment of NSCLC are whether three-drug are better than two-drug combinations, and whether cisplatin is still required.

Original languageEnglish
Pages (from-to)50-54
Number of pages5
JournalOncology
Volume65
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2003

Fingerprint

Ifosfamide
Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Cytostatic Agents
gemcitabine
Cisplatin
Taxoids
Survival
Mitomycin
Drug Combinations
Therapeutics
Drug Therapy

Keywords

  • Advanced stage
  • Ifosfamide
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ifosfamide in non-small cell lung cancer. / Boni, C.; Zanelli, F.

In: Oncology, Vol. 65, No. SUPPL. 2, 2003, p. 50-54.

Research output: Contribution to journalArticle

Boni, C. ; Zanelli, F. / Ifosfamide in non-small cell lung cancer. In: Oncology. 2003 ; Vol. 65, No. SUPPL. 2. pp. 50-54.
@article{62770b1e78ab498a940f048275438a11,
title = "Ifosfamide in non-small cell lung cancer",
abstract = "In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20-25{\%}. These results are improved when it is used in combination with cisplatin and mitomycin C. Moreover, in recent years, several new drugs like gemcitabine, taxanes and vinorelbine have been identified, and combinations of two or three drugs have been tested in patients with advanced NSCLC. This paper reviews the main studies recently conducted for the treatment of NSCLC, considering the results obtained by ifosfamide alone and in combination. Three-drug regimens including first-generation cytostatic agents achieve a response rate of about 40{\%} and median survival of 10 months. In combinations with new drugs, ifosfamide shows an improvement in response rate (50{\%}) with a median survival of more than 1 year. Open questions in the treatment of NSCLC are whether three-drug are better than two-drug combinations, and whether cisplatin is still required.",
keywords = "Advanced stage, Ifosfamide, Non-small cell lung cancer",
author = "C. Boni and F. Zanelli",
year = "2003",
doi = "10.1159/000073359",
language = "English",
volume = "65",
pages = "50--54",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Ifosfamide in non-small cell lung cancer

AU - Boni, C.

AU - Zanelli, F.

PY - 2003

Y1 - 2003

N2 - In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20-25%. These results are improved when it is used in combination with cisplatin and mitomycin C. Moreover, in recent years, several new drugs like gemcitabine, taxanes and vinorelbine have been identified, and combinations of two or three drugs have been tested in patients with advanced NSCLC. This paper reviews the main studies recently conducted for the treatment of NSCLC, considering the results obtained by ifosfamide alone and in combination. Three-drug regimens including first-generation cytostatic agents achieve a response rate of about 40% and median survival of 10 months. In combinations with new drugs, ifosfamide shows an improvement in response rate (50%) with a median survival of more than 1 year. Open questions in the treatment of NSCLC are whether three-drug are better than two-drug combinations, and whether cisplatin is still required.

AB - In recent years the role of chemotherapy in advanced non-small cell lung cancer (NSCLC) has been well established. Ifosfamide is an old drug still considered an effective cytostatic agent in the treatment of NSCLC. As a single agent, it has showed a response rate of 20-25%. These results are improved when it is used in combination with cisplatin and mitomycin C. Moreover, in recent years, several new drugs like gemcitabine, taxanes and vinorelbine have been identified, and combinations of two or three drugs have been tested in patients with advanced NSCLC. This paper reviews the main studies recently conducted for the treatment of NSCLC, considering the results obtained by ifosfamide alone and in combination. Three-drug regimens including first-generation cytostatic agents achieve a response rate of about 40% and median survival of 10 months. In combinations with new drugs, ifosfamide shows an improvement in response rate (50%) with a median survival of more than 1 year. Open questions in the treatment of NSCLC are whether three-drug are better than two-drug combinations, and whether cisplatin is still required.

KW - Advanced stage

KW - Ifosfamide

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0242351645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242351645&partnerID=8YFLogxK

U2 - 10.1159/000073359

DO - 10.1159/000073359

M3 - Article

C2 - 14586148

AN - SCOPUS:0242351645

VL - 65

SP - 50

EP - 54

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 2

ER -